Acyclovir has no effect on infectious mononucleosis, with its value in EBV encephalitis remaining unclear.( ) EBV encephalitis is
The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
The role of antiviral therapies in the treatment of acute and chronic EBV-associated disease is unclear. Acyclovir reduces EBV replication by inhibiting viral DNA polymerase, and studies have found that both acyclovir and the prodrug valacyclovir reduce oral shedding of EBV in patients with infectious mononucleosis.
EBV replicates during lytic infection by mechanisms common to all herpesviruses, and EBV lytic infection is inhibited by nucleoside analogues such as acyclovir
Acyclovir is an antiviral medication that inhibits DNA polymerase of EBV. Acyclovir s effects on IM have been studied in double-blind, placebo-controlled trials and have demonstrated a suppression in the shedding of EBV in the saliva of infected patients, but EBV replication resumed after treatment was discontinued. 12,13 The use of acyclovir
The role of antiviral therapies in the treatment of acute and chronic EBV-associated disease is unclear. Acyclovir reduces EBV replication by inhibiting viral DNA polymerase, and studies have found that both acyclovir and the prodrug valacyclovir reduce oral shedding of EBV in patients with infectious mononucleosis.
No effective antiviral therapy is available for Epstein-Barr virus (EBV) infectious mononucleosis in immunocompetent persons. Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV lymphoproliferative disease is controversial. Acyclovir has not been proven to be
by JC Luxton 2024 Cited by 22to receive acyclovir, EBV was not isolated from multi- ple throat washing dose oral acyclovir suppresses EBV replication in the oropharynx of most
Acyclovir is an antiviral medication that inhibits DNA polymerase of EBV. Acyclovir s effects on IM have been studied in double-blind, placebo-controlled trials and have demonstrated a suppression in the shedding of EBV in the saliva of infected patients, but EBV replication resumed after treatment was discontinued. 12,13 The use of acyclovir
Comments